4.8 Article

Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: a meta-analysis

期刊

LANCET
卷 380, 期 9854, 页码 1649-1661

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/S0140-6736(12)61272-0

关键词

-

资金

  1. Netherlands Organization for Scientific Research
  2. Dutch Kidney Foundation
  3. NFK
  4. Amgen
  5. NIH
  6. Servier
  7. Roche
  8. Sanofi
  9. Netherlands Heart Foundation
  10. Sanofi-Aventis
  11. Pfizer
  12. Merck Sharp Dohme Japan
  13. Dainippon Sumitomo Pharma
  14. Tanabe Mitsubishi Pharma
  15. Daiichi Sankyo Pharma
  16. Asterasu Pharma
  17. Kyowa Hakkou Kirin Pharma
  18. Takeda Pharma
  19. Bayer Health Care
  20. Abbott
  21. AstraZeneca
  22. Bristol-Myers Squibb
  23. Boehringer Ingelheim
  24. Lilly
  25. Novo Nordisk
  26. Novartis
  27. Baxter
  28. Fresenius
  29. GlaxoSmithKline
  30. Merck Sharp Dohme
  31. Merck
  32. Dutch Kidney Foundation (Nierstichting Nederland)
  33. US National Kidney Foundation
  34. Chief Scientist Office [CZH/4/656] Funding Source: researchfish

向作者/读者索取更多资源

Background Hypertension is the most prevalent comorbidity in individuals with chronic kidney disease. However, whether the association of the kidney disease measures, estimated glomerular filtration rate (eGFR) and albuminuria, with mortality or end-stage renal disease (ESRD) differs by hypertensive status is unknown. Methods We did a meta-analysis of studies selected according to Chronic Kidney Disease Prognosis Consortium criteria. Data transfer and analyses were done between March, 2011, and June, 2012. We used Cox proportional hazards models to estimate the hazard ratios (HR) of mortality and ESRD associated with eGFR and albuminuria in individuals with and without hypertension. Findings We analysed data for 45 cohorts (25 general population, seven high-risk, and 13 chronic kidney disease) with 1 127 656 participants, 364 344 of whom had hypertension. Low eGFR and high albuminuria were associated with mortality irrespective of hypertensive status in the general population and high-risk cohorts. All-cause mortality risk was 1.1-1.2 times higher in individuals with hypertension than in those without hypertension at preserved eGFR. A steeper relative risk gradient in individuals without hypertension than in those with hypertension at eGFR range 45-75 mL/min per 1.73 m(2) led to much the same mortality risk at lower eGFR. With a reference eGFR of 95 mL/min per 1.73 m(2) in each group to explicitly assess interaction, adjusted HR for all-cause mortality at eGFR 45 mL/min per 1.73 m(2) was 1.77 (95% CI 1.57-1.99) in individuals without hypertension versus 1.24 (1.11-1.39) in those with hypertension (p for overall interaction=0.0003). Similarly, for albumin-creatinine ratio of 300 mg/g (vs 5 mg/g), HR was 2.30 (1.98-2.68) in individuals without hypertension versus 2.08 (1.84-2.35) in those with hypertension (p for overall interaction=0.019). We recorded much the same results for cardiovascular mortality. The associations of eGFR and albuminuria with ESRD, however, did not differ by hypertensive status. Results for chronic kidney disease cohorts were similar to those for general and high-risk population cohorts. Interpretation Chronic kidney disease should be regarded as at least an equally relevant risk factor for mortality and ESRD in individuals without hypertension as it is in those with hypertension.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据